These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18205394)

  • 1. Hofmeister salts and potential therapeutic compounds accelerate in vitro fibril formation of the N-terminal domain of PABPN1 containing a disease-causing alanine extension.
    Lodderstedt G; Sachs R; Faust J; Bordusa F; Kühn U; Golbik R; Kerth A; Wahle E; Balbach J; Schwarz E
    Biochemistry; 2008 Feb; 47(7):2181-9. PubMed ID: 18205394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR.
    Rohrberg J; Sachs R; Lodderstedt G; Sackewitz M; Balbach J; Schwarz E
    FEBS Lett; 2008 May; 582(11):1587-92. PubMed ID: 18406354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1.
    Lodderstedt G; Hess S; Hause G; Scheuermann T; Scheibel T; Schwarz E
    FEBS J; 2007 Jan; 274(2):346-55. PubMed ID: 17229142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and dynamical characterization of fibrils from a disease-associated alanine expansion domain using proteolysis and solid-state NMR spectroscopy.
    Sackewitz M; Scheidt HA; Lodderstedt G; Schierhorn A; Schwarz E; Huster D
    J Am Chem Soc; 2008 Jun; 130(23):7172-3. PubMed ID: 18481858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD.
    Impagliazzo A; Tepper AW; Verrips TC; Ubbink M; van der Maarel SM
    FEBS Lett; 2010 Apr; 584(8):1558-64. PubMed ID: 20226184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1).
    Winter R; Kühn U; Hause G; Schwarz E
    J Biol Chem; 2012 Jun; 287(27):22662-71. PubMed ID: 22570486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trinucleotide expansions leading to an extended poly-L-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation.
    Scheuermann T; Schulz B; Blume A; Wahle E; Rudolph R; Schwarz E
    Protein Sci; 2003 Dec; 12(12):2685-92. PubMed ID: 14627730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
    Davies JE; Sarkar S; Rubinsztein DC
    Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.
    Davies JE; Berger Z; Rubinsztein DC
    Int J Biochem Cell Biol; 2006; 38(9):1457-62. PubMed ID: 16530457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1.
    Tavanez JP; Calado P; Braga J; Lafarga M; Carmo-Fonseca M
    RNA; 2005 May; 11(5):752-62. PubMed ID: 15811916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
    van der Sluijs BM; van Engelen BG; Hoefsloot LH
    Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
    Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
    Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unresolved puzzle why alanine extensions cause disease.
    Winter R; Liebold J; Schwarz E
    Biol Chem; 2013 Aug; 394(8):951-63. PubMed ID: 23612654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
    Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
    J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
    Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
    Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.
    Chartier A; Raz V; Sterrenburg E; Verrips CT; van der Maarel SM; Simonelig M
    Hum Mol Genet; 2009 May; 18(10):1849-59. PubMed ID: 19258344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
    Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G>C; p.Gly12Ala point mutation.
    Robinson DO; Hilton-Jones D; Mansfield D; Hildebrand GD; Marks S; Mechan D; Ramsay J
    Neuromuscul Disord; 2011 Nov; 21(11):809-11. PubMed ID: 21742497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.
    Messaed C; Dion PA; Abu-Baker A; Rochefort D; Laganiere J; Brais B; Rouleau GA
    Neurobiol Dis; 2007 Jun; 26(3):546-57. PubMed ID: 17418585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
    Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.